MarginsXMarginsX
Home › Markets › Health Care › UPC

Universe Pharmaceuticals Inc. (UPC)

UPC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.48
-1.99% on the day
Market cap
$7.4M
Nano cap
Revenue · 2025
$17.9B
-22.4% on 2024
Net income · 2025
-$3.7B
-20.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-09-30, https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/0001213900-26-009000-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-09-30.

Profile

FieldValue
TickerUPC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryChina
IPO year2021
SEC CIK0001809616

Financials · 2025

LineValue
Revenue$17.9B
Net income-$3.7B
Operating income-$2.9B
Net margin-20.6%
Operating margin-16.3%
Revenue growth-22.4%
Cash$33.6B
Total assets$69.3B
P/E (computed)Net income was not positive
P/S (computed)0.0×

Warning signs

Cash runway
79.8 months
$33.6B cash at September 30, 2025
Share count, 1 year
See the dilution note
+9224.2% over 3 years
Going-concern doubt
No
20-F filed January 29, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-01-29
Cash and burn$33.6B cash; operating cash flow -$1.3B a quarter.Report 2025-09-30
Shares outstandingNo cover-page share count in XBRLCover page 2025-09-30
Reverse splits, 3 years2; latest 1-for-40 on 2025-03-24Source 2025-03-24
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorENROME LLP, Singapore, SingaporePCAOB Form AP 2026-02-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-09-30
$17.9B-$3.7B-$5.1B$33.6B$9.3B$17.9B20-F 2026-01-29
FY 2024
2024-09-30
$23.0B-$8.7B-$9.5B$29.5B$5.9B$23.0B20-F 2026-01-29
FY 2023
2023-09-30
$32.3B-$6.6B$1.1B$5.3B$5.5M$32.3B20-F 2026-01-29
FY 2022
2022-09-30
$40.1M-$7.9M-$1.3M$5.7B$3.9M$40.1M20-F 2025-04-29
FY 2021
2021-09-30
$48.0M$11.3M-$2.1M$8.1M$4.3M$48.0M20-F 2024-01-30
FY 2020
2020-09-30
$30.7M$7.6M$6.1M$10.1M$2.6M$30.7M20-F 2023-02-10
FY 2019
2019-09-30
$33.2M$7.6M$13.2M$3.2MNo debt tags$33.2M20-F 2022-01-31

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+8.6%
1 month-64.6%
3 months-74.3%
Year to date-60.4%
1 year-59.6%
From 52-week high-87.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MBRXMoleculin Biotech Inc.$7.14-9.28%$7.6M
GTBPGT Biopharma Inc.$3.54-1.81%$7.3M
CURXCuranex Pharmaceuticals Inc$4.63-0.11%$7.3M
IMRNImmuron Limited$0.8996+2.23%$7.3M
LGVNLongeveron Inc.$2.14-14.06%$7.2M
XCURExicure Inc.$1.07-0.93%$7.0M
ENSCEnsysce Biosciences Inc.$0.4095-2.13%$8.0M
RKTORocket One Inc.$0.3210+0.03%$8.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier